Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 in moderate to severe active Crohn's disease
NCT00584740Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2008
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in Crohn's disease, sponsored by Novartis. Started Aug 2008; status: terminated.
02
Drugs
secukinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00584740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00584740.